The confirmed chairs for these sessions are:

-José Antonio Mayoral, Dean of the University of Zaragoza.

-Liesbet Geris, Director of VPH Institute.

-José Ángel Castellanos, Director of the EINA.

-Ignacio Garcés, Director of I3A.

-Pilar Alegría, Goverment of Aragón

Liesbet Geris – VPHi Executive Director: “The VPH Institute: promoting in silico medicine research” and “the VPHi FP9 Position Paper”

Violeta Isabel Pérez Nueno - European Commission Officer: “Future priorities of in-silico medicine”

Tina Morrison (FDA): "FDA research priorities for in silico medicine"

 Q&A

ATTRACTIVE OPPORTUNITIES FOR YOUNG RESEARCHERS IN EUROPEAN PROJECTS (H2020)

This talk will show an overview of different opportunities for young researchers in the frame of European Projects (H2020).

In order to cover all the aspects involved in a proposal preparation, both the formal issues of the calls as well as success cases will be presented.

Fundamental elements regarding preparation of the proposal will be reviewed, with particular emphasis on the definition of the problem that wants to be solved, its significance and the selection of an innovative methodology to tackle it.

Based on previous experiences of H2020 applicants, tips will be provided on: the importance of identifying the best moment to present the proposal; the time you should reserve to not only write but more crucially to think about your idea; or the benefit of seeking for advice from colleagues with expertise in different disciplines, not necessarily close to yours.

Finally, the talk will go over the way you report your CV and your past achievements and how this can influence how others may or may not see you as the best possible researcher to carry out the project you are presenting.

16:30-17:15 Elena Portero – UNIZAR European Project Office & Francisco Gaspar – MSCA granted researcher: “MSC Actions Individual Fellowships: Formal Issues, Success case experience and Q&A”
17:15-18:00 Elena Portero – UNIZAR European Project Office & Esther Pueyo – ERC granted researcher: “ERC Starting Grants: Formal Issues, Success case experience and Q&A”

18:05 – 18:15: Lies Geris – VPHi Executive Director: “Introduction on the scope of the session”

18:15 – 18:25: Martina Contin – VPHi Manager ”VPHi as a project partner: community engagement and outreach”

18:25– 19:00: Juan Riese – Spanish NCP: “Presentation of the VPH related calls in last work program of H2020”

19:00: – 19:30: Q&A session on H2020 calls

19:30 – 20:30: Networking session – Drinks and small buffet

10:30 – 10:40: “Welcome and Introduction to ANSYS”; Thierry Marchal, Global Industry Director Healthcare, ANSYS

10:40 – 11:05: “Computational-based MRI Thermal Injury Risk Assessment for Patients implanted with Passive Spinal Devices”; Payman Afshari, Sr. Principal Engineer at DePuy Synthes Spine, Johnson and Johnson

11:05 – 11:30: “Getting to Know Your Digital Twin”; Marc Horner, Technical Lead Healthcare North America, ANSYS

11:30 – 11:55: "Why In Silico Healthcare is important for Medtronic?"; Mark Palmer, Senior Principal Scientist, Science Technology & New Therapies, Medtronic

11:55 – 12:20: “An on-line platform to facilitate in silico clinical trials while complying to FDA guidances”; Luca Emil, CEO In Silico Trials Technologies

12:20 – 12:30: Wrap up & Discussion, Thierry Marchal

Technology transfer and access: challenges and opportunities

In the last decades, universities and research centers have been applying modeling and simulation (M&S) to problems involving health and medicine, coining the new expression in silico clinical trials, but its use is still limited to a restricted pool of expert adopters.

Making M&S available to a broad spectrum of potential users (medical device and pharmaceutical companies, hospitals, healthcare institutions) would require an easy and controlled access to models and computational resources in a secure and compliant environment while protecting the intellectual property of the models’ creators.

Meanwhile, the European and USA regulatory agencies are starting to recognize the use of M&S in the research and technological development and to provide evidence in the approval process for new medical products. A joint effort from academia, industry and regulatory bodies is then required to reach a rapid adoption of a harmonized approach.

In this session, we will talk about potentials, limitations, challenges, and opportunities that the community has to deal with to leverage the significant value of M&S solutions which are being developed but are not fully exploited, in order to reach a broad adoption and democratization of simulations in healthcare.

Session topics:

• 14:00 – 14:15 Is there a "Valley of Death" for in silico medicine technologies? - Marco Viceconti, Executive Director at Insigneo Institute for in silico Medicine
• 14:15 – 14:30 In silico modelling: From lab to the end-users - Javier Saiz, Professor at Universidad Politécnica de Valencia
• 14:30 – 14:45 Learning from other industries: exploiting world class research to accelerate industrial innovations - Thierry Marchal, ANSYS Global Industry director
• 14:45 – 15:00 One model for all and all efforts as one! - Nico Verdonschot, Scientific Director of Technical Medical Center at University of Twente
• 15:00 – 15:15 Commercializing Computational Models of Inflammation: Past, Present, and Future - Yoram Vodovotz, Director at Center for Inflammation and Regenerative Modeling, University of Pittsburgh
• 15:15 – 15:30 Technology transfer and technology access. How InSilicoTrials is working with researchers and industry – Luca Emili, CEO at InSilicoTrials Technologies
• 15:30 – 16:00 Round Table, moderator: Luca Emili, CEO at InSilicoTrials Technologies

Target: Industry specialists (product developers, regulatory affair, clinical trialists, etc.)

Tentative programme

16:30 – 16:45  The emerging regulatory landscape for in silico methods – Tina Morrison, FDA

16:45 – 17:30  Tools and services for in silico clinical trials: Moderator: Thierry Marchal, Avicenna Alliance.

                        Ansys – Representative.

                        Materialise – Sjoerd Kolk.

                        InsilicoTrials – Luca Emili.

                        Quibim – Angel Alberich-Bayarri.

17:30 – 17:45  In silico Clinical Trials: A vision of the future: Marco Viceconti, Insigneo Institute

17:45 – 18:00  Examples of early applications: Mark Palmer, Medtronic

18:00 – 18:10  Scalability of Computational Medicine applications: Peter Coveney, CompBioMed CoE

18:10 – 18:45  Round table. Moderator: Thierry Marchal, Avicenna Alliance